Lyophilized syringin powder for injection is developed independently by Renhuang as a new form of pure Chinese herbal medicine that does not have any of the side-effects of other synthetic anti-depression drugs commonly used by patients around the world. Renhuang is in the process to file an invention patent application for this new drug with the State Intellectual Property Office of the P.R.C (SIPO). The product is expected to be classified as a “Class One” new drug by SFDA representing a major breakthrough in anti-depression drug development worldwide. This new drug can also be used as anti-exhaustion treatment, wound stancher and healthy gland growth nutrition.

Mr. Li Shaoming, chief executive officer of Renhuang, said, “ Although rapid economic development is raising standards of living in China and improving the lives of many, Chinese people are increasingly confronted with stress brought about by economic development and increased competition. At the same time, they are becoming more health conscious and more sophisticated in their understanding of medical treatments. Given the high risks of side effects from current anti-depression drugs, both physicians and patients around the world are yearning for anti-depression medication treatments with low or zero side-effects. This creates substantial market potential globally for our new anti-depression drug. We are very confident that this new drug will not only help Renhuang expand its market share in China but it will also increase Renhuang’s brand awareness overseas.”

By controlling an estimated 70% of China’s natural resource of Acanthopanax (also known as Siberian Ginseng), a raw material, from which syringin is extracted, securing ample supply for the new drug and minimizing raw material cost.

According to a 2006 report by the World Heath Organization, there were about 340 million people suffering from depression in the world including more than 26 million in China as per the latest statistics from the China Association for Mental Health. Global sales of anti-depression drugs reached US $20.60 billion in 2006.

Renhuang has secured prime time advertising slots on China Central Television Station (CCTV) in 2008. Advertising during the Beijing Olympics, in particular, will provide a unique platform to substantially increase Renhuang’s brand recognition in China and around the world.

About Renhuang Pharmaceuticals, Inc.

Renhuang Pharmaceuticals, located in Harbin, Heilongjiang province, in Northeast China, is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, Shark Power Health Care series (a natural marine biology product), and Traditional Medical Products, currently representing 53%, 12%, and 35% of total revenues, respectively. Renhuang has a dominant market position in Acanthopanax-derived products, controlling an estimated 70% of China’s natural resource of Acanthopanax (also known as Siberian Ginseng) that grows in Heilongjiang province but does not grow in abundance anywhere else in China. Siberian Ginseng has become one of the most popular natural medicinal products in the world due to its well known ability to help people enhance overall health, improve memory, relieve stress, combat fatigue, restore energy, and increase endurance.

Renhuang distributes its products through a sales network of over 2000 sales agents organized under 70 sales centers across 24 districts that cover over 50% of the greater China. Beginning in 2007, the Company has started to sell some of its products under its own brand in Russia and expects that this new market will generate substantial revenue growth.

The Company has established a multi-channel research and development infrastructure composed of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. A state of the art research center is currently supporting the development of numerous product innovations including food antiseptic, immune system and diagnostic products. Several of these products have already been submitted for approval by the State Food and Drug Administration (“SFDA”). These products are 60% more reliable than those currently on the market and are expected to have a substantial upside growth potential due to their insufficient supply in China. The Company has received numerous grants from the central and local governments, attesting to the high quality of its operations and its demonstrated ability to lead in innovation and technology.

Safe Harbor Statement

This press release contains certain statements that may include 'forward-looking statements' as defined in the Securities Act of 1933, and the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are 'forward-looking statements.' Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.